Compare PMN & AEYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMN | AEYE |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.1M | 86.2M |
| IPO Year | 2022 | 2011 |
| Metric | PMN | AEYE |
|---|---|---|
| Price | $8.15 | $6.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $42.73 | $17.33 |
| AVG Volume (30 Days) | 28.7K | ★ 63.8K |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $40,311,000.00 |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | N/A | $10.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.52 |
| 52 Week Low | $0.29 | $5.31 |
| 52 Week High | $27.40 | $16.39 |
| Indicator | PMN | AEYE |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 43.11 |
| Support Level | $7.98 | $6.61 |
| Resistance Level | $8.75 | $7.32 |
| Average True Range (ATR) | 0.92 | 0.31 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 7.82 | 9.76 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.